157 related articles for article (PubMed ID: 32707803)
1. Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses.
Jeon I; Lee JM; Shin KS; Kang T; Park MH; Seo H; Song B; Koh CH; Choi J; Shin YK; Kim BS; Kang CY
Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32707803
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer.
Jung M; Lee JB; Kim HS; Kwon WS; Kim HO; Kim S; Park M; Kim W; Choi KY; Oh T; Kang CY; Chung HC; Rha SY
Cancer Res Treat; 2024 Jan; 56(1):208-218. PubMed ID: 37402409
[TBL] [Abstract][Full Text] [Related]
3. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
4. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
5. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
6. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.
Choi CH; Choi HJ; Lee JW; Kang ES; Cho D; Park BK; Kim YM; Kim DY; Seo H; Park M; Kim W; Choi KY; Oh T; Kang CY; Kim BG
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31948126
[No Abstract] [Full Text] [Related]
8. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
Cho HM; Rosenblatt JD; Kang YS; Iruela-Arispe ML; Morrison SL; Penichet ML; Kwon YG; Kim TW; Webster KA; Nechustan H; Shin SU
Mol Cancer Ther; 2005 Jun; 4(6):956-67. PubMed ID: 15956253
[TBL] [Abstract][Full Text] [Related]
9. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
10. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
11. Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model.
Tahaghoghi-Hajghorbani S; Tavakkol-Afshari J; Jaafari MR; Ghaffari-Nazari H; Masoumi E; Jalali SA
Anticancer Agents Med Chem; 2017; 17(6):851-858. PubMed ID: 27924731
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures.
Kim EK; Seo HS; Chae MJ; Jeon IS; Song BY; Park YJ; Ahn HM; Yun CO; Kang CY
Gene Ther; 2014 Jan; 21(1):106-14. PubMed ID: 24225639
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats.
Bhattachary R; Bukkapatnam R; Prawoko I; Soto J; Morgan M; Salup RR
Int Immunopharmacol; 2002 May; 2(6):783-96. PubMed ID: 12095169
[TBL] [Abstract][Full Text] [Related]
14. Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine.
Zhang W; Wang S; Gu J; Gao Y; Wang Z; Zhang K; Mu N; Huang T; Li W; Hao Q; Xue X; Zhang W; Zhang Y; Zhang C
Biochem Biophys Res Commun; 2018 Feb; 497(1):394-400. PubMed ID: 29438713
[TBL] [Abstract][Full Text] [Related]
15. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity.
Tian H; He Y; Song X; Jiang L; Luo J; Xu Y; Zhang W; Gao X; Yao W
Cancer Lett; 2018 Aug; 430():79-87. PubMed ID: 29778570
[TBL] [Abstract][Full Text] [Related]
16. A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
Gallou C; Rougeot A; Graff-Dubois S; Kosmatopoulos K; Menez-Jamet J
Oncotarget; 2016 Sep; 7(37):59417-59428. PubMed ID: 27506946
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
Maruyama H; Zaloudik J; Li W; Sperlagh M; Koido T; Somasundaram R; Scheck S; Prewett M; Herlyn D
Cancer Immunol Immunother; 2000 Jun; 49(3):123-32. PubMed ID: 10881691
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
19. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
[TBL] [Abstract][Full Text] [Related]
20. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]